New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making: New and Emerging Biological Therapies for Myasthenia Gravis: L. Gerischer et al.
- Published in:
- 2025
- By:
- Publication type:
- Literature Review
Works matching IS 11738804 AND DT 2025 AND VI 39 AND IP 2
Results: 10
1
2
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back: Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: A. Mariniello et al.
- Published in:
- 2025
- By:
- Publication type:
- Literature Review
3
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome: Development and Impact of Eculizumab Biosimilars for PNH and aHUS: J. H. Jang et al.
- Published in:
- 2025
- By:
- Publication type:
- Literature Review
4
An Automated Tool for Glycosimilarity Assessment of mAb Therapeutic Biosimilars: Trastuzumab and Bevacizumab as Case Studies: An Automated Tool for Glycosimilarity Assessment of mAb Therapeutic Biosimilars: A. Shrivastava et al.
- Published in:
- BioDrugs, 2025, v. 39, n. 2, p. 333, doi. 10.1007/s40259-025-00704-6
- By:
- Publication type:
- Article
5
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects: Islet Cell Replacement and Regeneration for T1D: A. R. Tondin, G. Lanzoni.
- Published in:
- 2025
- By:
- Publication type:
- Literature Review
6
State-of-the-Art Liver Cancer Organoids: Modeling Cancer Stem Cell Heterogeneity for Personalized Treatment: Modeling Liver CSC Heterogeneity with Organoids for Personalized Treatment Strategies: J. Giron-Michel et al.
- Published in:
- 2025
- By:
- Publication type:
- Literature Review
7
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review: TL1A Inhibition in IBD: V. Solitano et al.
- Published in:
- 2025
- By:
- Publication type:
- Literature Review
8
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network: IL23is and IL17is for Preventing PsA: S. Yu et al.
- Published in:
- BioDrugs, 2025, v. 39, n. 2, p. 297, doi. 10.1007/s40259-025-00705-5
- By:
- Publication type:
- Article
9
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study: Nationwide Study of Wegovy Use: N. Haddy et al.
- Published in:
- BioDrugs, 2025, v. 39, n. 2, p. 321, doi. 10.1007/s40259-024-00699-6
- By:
- Publication type:
- Article
10
Comparative Structure Activity Relationship Characterization of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab: Structure Activity Relationship Characterization of BAT1806/BIIB800 to Reference Tocilizumab: Y. Liu et al.
- Published in:
- BioDrugs, 2025, v. 39, n. 2, p. 307, doi. 10.1007/s40259-024-00698-7
- By:
- Publication type:
- Article